Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Friedrichshall – page 4

851 clinical trials in Bad Friedrichshall, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Friedrichshall at a glance
851
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

851 trials in Bad Friedrichshall

Open in trial search

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Osteomyelitis

Recruiting

Early switch to oral amoxicillin (drug combination) for adults with vertebral osteomyelitis: a randomised non‑inferiority trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:University Of Cologne

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on Zanidatamab with Cisplatin and Gemcitabine for Advanced HER2 Positive Biliary Tract Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Breast cancer

Recruiting

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:PIPE-791
  • Sponsor:Contineum Therapeutics Inc.

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Ifinatamab deruxtecan in Patients With Advanced Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Friedrichshall

What the registry says about research in the country

01 Cardiovascular Disease Research

Clinical trials focusing on atherosclerotic cardiovascular disease are evaluating innovative therapies to reduce major adverse cardiovascular events. These studies aim to improve outcomes for patients at high cardiovascular risk.

  • Coronary Heart Disease
  • Myocardial Infarction
  • Ischemic Stroke Prevention

Research emphasizes the development of new therapeutic approaches for arterial health management.

02 Heart Failure Studies

Groundbreaking research combines empagliflozin with novel compounds to address heart failure management. These trials specifically target patients with reduced left ventricular ejection fraction.

  • Combination Therapy Assessment
  • Cardiovascular Mortality Reduction
  • Hospital Admission Prevention

The studies aim to enhance current treatment protocols for heart failure patients.

03 Cardiac Rhythm Management

Important clinical research in atrial fibrillation and acute coronary syndrome is evaluating new anticoagulation strategies. These trials focus on preventing cardioembolic events and improving post-heart attack outcomes.

  • Stroke Prevention
  • Systemic Embolism Prevention
  • Post-Heart Attack Care

The research aims to establish more effective therapeutic options for cardiac patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.